Skip to main content

Table 2 Clinical outcome variables (adjusted using SuperLearner)

From: Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study

 

IGAM group (n = 146)

Controls (n = 170)

HRadjusted (95%-CI)

p value

Primary outcome

    

30-day mortality, n (%)

42 (28.8%)

54 (31.8%)

0.83 (0.55 to 1.25)

0.374

Secondary outcomes, median [IQR]

    

Organ support-free days at 30 days

0 [-1; 10]

0 [-1; 22]

1.03 (0.81 to 1.32)

0.817

 Ventilator-free days at 30 days

0 [-1; 16]

1 [-1; 22]

1.10 (0.87 to 1.38)

0.443

 Vasopressor-free days at 30 days

0 [-1; 21.5]

1.5 [-1; 29]

1.00 (0.79 to 1.26)

0.994

Dialysis-free days at 30 days

9 [-1; 19]

8.5 [-1; 19]

1.03 (0.79 to 1.34)

0.828

ICU length of stay

24 [14; 40]

20 [10; 34]

n/a

0.040

 ICU-free days at 30 days

0 [-1; 4]

0 [-1; 6]

n/a

0.943

Hospital length of stay

33 [20; 50]

25.5 [16; 42]

n/a

0.010

  1. IGAM IgM-enriched intravenous immunoglobulins; ICU intensive care unit